Anticonceptivos, causan trombosis en mujeres transexuales y sexoservidoras (página 2)

53. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003; 88:3467- 73.

54. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.Ann N Y Acad Sci1995; 761: 311-35.

55. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study.J Thromb Haemost 2007; 5:692-9.

56. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid , drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.J Clin Endocrinol Metab1995;80:1816-21.

57. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3"-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.

58. Porter JB. Oral contraceptives and nonfatal vascular disease — recent experience. Obstet Gynecol 1982; 59: 299-302.

59. Prasad RN, Koh SC, Viegas OA, Ratnam SS. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel. Clin Appl Thromb Hemost 1999; 5:60-70.

60. Records Unit and Research Advisory Service of the Royal College of General Practioners. Oral contraception and thrombo-embolic disease. J R Coll Gen Pract 1967; 13: 267-79.

61. Reuner KH, Ruf A, Grau A, Rickmann H, Stolz E, Jüttler E, et al. A transition is a risk factor for cerebral venous thrombosis. Stroke (1998) 29:1765-9.

62. Rintelen C, Mannhalter C, Ireland H, Lane DA, Knobl P, Lechner K, Pabinger I. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996; 93: 487-90.

63.  Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.

64. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis Thromb Haemost 2001; 86:112-23.

65. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.

66. Rosing J, Curvers J, Tans G. Oral contraceptives, thrombosis and haemostasis. Eur J Obstet Gynecol Reprod Biol 2001; 95:193-7.

67. Rosing J, Middeldorp S, Curvers J, Christela M, Thomassen LG, Nicolaes GA, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354:2036-40.

68. Rosing J, Tans G, Nicolaes GA, Thomanssen MC, Van der Oerle R, Van der Ploeg PM. Oral contraceptives and venous trombosis: different sensitivies to activated protein C in women using second-and third generation oral contraceptives. Br J Haematol 1997; 97:233-8.

69. Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol (1997) 97:233-8..

70. Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2011) 42:1158-92.

71. Sapp AV, Lindbloom EJ. Do third-generation oral contraceptives (OCs) increase the risk of venous thrombosis? J Fam Pract (2001) 50:893.

72. Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiological case-control study. Am J Epidemiol 1969; 90: 365-80.

73. Schlatterer K, Yassouiridis A, von Werder K, Polonia D, Kemper J, Stalla GK. Un estudio de seguimiento a la estimación de la eficacia de una terapia de sustitución hormonal de género cruzado en pacientes transexuales. Archives of Sexual Behavior, 1998; 27: 475-492…

74. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/ drospirenone and other oral contraceptives.Obstet Gynecol 2007; 110:587-93.

75. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312:83-8.

76. Spitzer WO. El acetato de ciproterona con etinilestradiol como un factor de riesgo de tromboembolismo venoso: una evaluación epidemiológica. J Obstet Gynaecol Can. 2003 Dec;25(12):1011-8.

77. Stegeman BH, deBastos M, Rosendaal FR, van Hylckama Vlieg A, Helmerhorst FM, Stijnen T, Dekkers OM. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013; 347: f5298.

78. Stolley PD, Tonascia JA, Tockman MS, Sartwell PE, Rutledge AH, Jacobs MP. Thrombosis with low-estrogen oral contraceptives. Am J Epidemiol 1975; 102: 197-208.

79. Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception (1997) 56:141-6.

80. Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC, Prins MH, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84:15-21.

81. Tans G, van Hylckama Vlieg A, Thomassen MCLGD, Curvers J, Bertina RM, Rosing J, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women.Br J Haematol2003; 122:465-70.

82. The Coronary Drug Project Research Group. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. JAMA 1973; 226: 652-7.

83. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992; 21: 48-52

84. Van Kesteren P, Lips P, Gooren LJG, Asscheman H, Megens J (1998) A largo plazo de seguimiento de la densidad mineral ósea en los transexuales tratados con hormonas del sexo opuesto. Clinical Endocrinology 48: 347-354

85. Van Kesteren P, Megens JAJ, Asscheman H, efectos. Gooren LJG secundarios de la administración hormonal del sexo en transexuales. Clinical Endocrinology, 1997; 47: 337-342

86. Van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997; 47: 337-42..

87. Van Vliet HA, Frolich M, Christella M, Thomassen MCLGD, Doggen CJM, Rosendaal FR, et al. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.Hum Reprod 2005; 20:563-8.

88. Van Vliet HA, Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate.J Thromb Haemost 2004; 2:2060-2.

89. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.

90. Vasilakis C, Jick SS, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception 1999; 59: 79-83.

91. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J 1968; 2: 199-205.

92. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report. Br Med J 1969; 2: 651-7.

93. Villa P, Aznar J, Mira Y, Fernandez MA, Vaya A. Third-generation oral contraceptives and low free protein S as a risk for venous thrombosis. Lancet (1996) 347:397.

94. Wagstaff A. Socioeconomic inequalities in child mortality: comparisons across nine developing countries. Bull World Health Organ (2000) 78:19-29.

95. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346:1575-82.

96. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346:1582-8.

97. World Health Organization. Cardiovascular disease and steroid hormone contraception. Report of a WHO Technical Report Series Geneva: WHO, 1998.

98. Yahyaoui R, Esteva I, Haro-Mora JJ, et al. Effect of long-term administration of cross-sex hormone therapy on serum and urinary acid in transsexual persons. J Clin Endocrinol Metab 2008; 93:2230-3.